new products
P339-SHANK3
Autism Spectrum Disorder
P010-POLG
Mitochondrial maintenance
P366-CHM-RP2-RPGR
Retinitis pigmentosa (RP)
P350-CLCN1-KCNJ2
Myotonia congenita, Thomsen’s disease, Becker’s disease, Andersen-Tawil syndrome
P273-PCSK5
Atherosclerotic cardiovascular disease (risk of)

improved products
P044-NF2
Neurofibromatosis type 2 (NF2)
P199-HEXA
Tay-sachs disease
P214-COL2A1
Skeletal disorders, Achondrogenesis, Chondrodysplasia, Early onset familial Osteoarthritis, SED congenital, Langer-Saldino achondrogenesis, Kniest dysplasia, Stickler syndrome, Spondyloepimetaphyseal
P280-SLC26A4
Pendred syndrome
P026-Sotos
Sotos syndrome
ME011-MMR
Mismatch repair genes (MMR)
About MRC-Holland
MRC-Holland b.v. is a biotechnology company located in Amsterdam, the Netherlands. The company is a follow-up of Microbiology Research Centre Holland, founded in 1985 by Dr. Jan Schouten. Until 2000, the main products of MRC-Holland were restriction endonucleases -purified from a wide range of bacteria and blue green algae- and DNA molecular weight markers. These products were sold in bulk amounts to distributing companies worldwide.

In 1997, MRC-Holland started focusing on developing new techniques for DNA analysis. By far the most successful technique developed is Multiplex Ligation-dependent Probe Amplification, or MLPA®. The MLPA® technology was first described in Nucleic Acid Research 30, e57 (2002) by Schouten et al. Since then, hundreds of MLPA probe sets have been developed for a wide variety of genes and applications, some of which very rare.

At present, all activities of MRC-Holland are directed to the production of new MLPA-based products and the development of novel MLPA-based techniques, such as the MS-MLPA technique for DNA methylation testing. MRC-Holland currently has about 40 employees, working in development, quality testing, production, sales and customer service.
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2010 MRC-Holland